The Caesarea, Israel-based company said roughly 53% of its shares were represented in the vote, with about 95% of those cast in favor of the $58.50-per-ADR-share deal.
The world’s largest medical device maker has held a position in Mazor, which makes the Mazor X guidance system and the Renaissance robot-assisted spine surgery platform, since May 2016. In September they closed the third, $40 million tranche of that investment, giving Medtronic a 10.6% stake for $72 million.
Medtronic has said it plans to develop a fully-integrated surgical planning, execution and confirmation system by uniting its existing spine technologies with the Mazor robotic system once the deal closes, expected during Medtronic’s fiscal third quarter ending Jan. 25.
DeviceTalks West is just a few days away. Join more than 300 of your peers for a day of world-class education, networking, and a technology exhibition featuring the leading companies in the industry.
Don’t miss out on this premier opportunity to come together and share perspectives with the best of the best in the industry.
Use code LASTCHANCE to save an additional 20%.